RTA Laboratuvarlari Biyolojik (IS:RTALB) — Market Cap & Net Worth
Market Cap & Net Worth: RTA Laboratuvarlari Biyolojik (RTALB)
RTA Laboratuvarlari Biyolojik (IS:RTALB) has a market capitalization of $39.31 Million (TL1.75 Billion) as of June 22, 2026. Listed on the IS stock exchange, this Turkey-based company holds position #22804 globally and #398 in its home market, demonstrating a 0.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RTA Laboratuvarlari Biyolojik's stock price TL3.51 by its total outstanding shares 500000000 (500.00 Million). Review how much debt does RTA Laboratuvarlari Biyolojik carry to assess the company's total debt and financial obligations.
RTA Laboratuvarlari Biyolojik Market Cap History: 2015 to 2026
RTA Laboratuvarlari Biyolojik's market capitalization history from 2015 to 2026. Data shows growth from $12.91 Million to $39.31 Million (10.60% CAGR).
RTA Laboratuvarlari Biyolojik Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RTA Laboratuvarlari Biyolojik's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.02x
RTA Laboratuvarlari Biyolojik's market cap is 1.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.11x
RTA Laboratuvarlari Biyolojik's market cap is 3.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $12.91 Million | $33.68 Million | $7.48 Million | 0.38x | 1.73x |
| 2016 | $9.00 Million | $31.81 Million | $4.09 Million | 0.28x | 2.20x |
| 2017 | $12.39 Million | $38.45 Million | $4.16 Million | 0.32x | 2.98x |
| 2018 | $7.81 Million | $20.47 Million | $601.21K | 0.38x | 12.99x |
| 2019 | $11.16 Million | $16.77 Million | $4.42 Million | 0.67x | 2.52x |
| 2020 | $145.71 Million | $230.44 Million | $60.93 Million | 0.63x | 2.39x |
| 2021 | $106.54 Million | $384.34 Million | $114.47 Million | 0.28x | 0.93x |
| 2022 | $145.47 Million | $86.03 Million | $281.12 Million | 1.69x | 0.52x |
| 2023 | $160.59 Million | $138.51 Million | -$103.16 Million | 1.16x | N/A |
| 2024 | $162.49 Million | $158.59 Million | $52.23 Million | 1.02x | 3.11x |
Competitor Companies of RTALB by Market Capitalization
Companies near RTA Laboratuvarlari Biyolojik in the global market cap rankings as of June 22, 2026.
Key companies related to RTA Laboratuvarlari Biyolojik by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
RTA Laboratuvarlari Biyolojik Historical Marketcap From 2015 to 2026
Between 2015 and today, RTA Laboratuvarlari Biyolojik's market cap moved from $12.91 Million to $ 39.31 Million, with a yearly change of 10.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | TL39.31 Million | +2.33% |
| 2025 | TL38.41 Million | -76.36% |
| 2024 | TL162.49 Million | +1.19% |
| 2023 | TL160.59 Million | +10.39% |
| 2022 | TL145.47 Million | +36.54% |
| 2021 | TL106.54 Million | -26.88% |
| 2020 | TL145.71 Million | +1205.19% |
| 2019 | TL11.16 Million | +42.90% |
| 2018 | TL7.81 Million | -36.95% |
| 2017 | TL12.39 Million | +37.66% |
| 2016 | TL9.00 Million | -30.26% |
| 2015 | TL12.91 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of RTA Laboratuvarlari Biyolojik was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.31 Million USD |
| MoneyControl | $39.31 Million USD |
| MarketWatch | $39.31 Million USD |
| marketcap.company | $39.31 Million USD |
| Reuters | $39.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RTA Laboratuvarlari Biyolojik
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, paint… Read more